recombinant factor VIII; turoctocog alfa; (Factorate, Recombinate, Xyntha, Kogenate FS, Kovaltry, NovoEight)
Jump to navigation
Jump to search
Introduction
Tradenames: Factorate, Recombinate, Xyntha (from CHO cells)
Indications
- management of hemophilia A
Contraindications
- hypersensitivity to mouse proteins (preparation contains trace amounts of mouse protein
Dosage
- individualize dose based upon coagulation studies
- one unit will increase circulating AHF by 2%
- hospitalized patients:
- 20-50 units/kg/dose
- may be given every 12-24 hours & more frequently in special circumstances
AHF units = body weight (kg) x desired AHF increase (%) x 0.5
Injection: 250, 500, 1000 units.
Pharmacokinetics
Adverse effects
- uncommon (< 1%)
- flushing, tachycardia, headache, nausea/vomiting, paresthesia, allergic vasomotor reactions, tightness in neck or chest
More general terms
More specific terms
Component of
References
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
- ↑ Brooks M FDA Clears Factor VIII Product Kovaltry for Hemophilia. Medscape March 17, 2016 http://www.medscape.com/viewarticle/860577
- ↑ Al-Salama ZT, Scott LJ. Lonoctocog Alfa: A Review in Haemophilia A. Drugs. 2017 Oct;77(15):1677-1686. PMID: https://www.ncbi.nlm.nih.gov/pubmed/28900904 Free PMC Article